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Tissue effector cells of the monocyte lineage can
differentiate into different cell types with specific
cell function depending on their environment. The
phenotype, developmental requirements, and func-
tional mechanisms of immune protective macro-
phages that mediate the induction of transplantation
tolerance remain elusive. Here, we demonstrate that
costimulatory blockade favored accumulation of
DC-SIGN-expressing macrophages that inhibited
CD8+ T cell immunity and promoted CD4+Foxp3+
Treg cell expansion in numbers. Mechanistically,
that simultaneous DC-SIGN engagement by fucosy-
lated ligands and TLR4 signaling was required for
production of immunoregulatory IL-10 associated
with prolonged allograft survival. Deletion of DC-
SIGN-expressing macrophages in vivo, interfering
with their CSF1-dependent development, or prevent-
ing the DC-SIGN signaling pathway abrogated toler-
ance. Together, the results provide new insights into
the tolerogenic effects of costimulatory blockade
and identify DC-SIGN+ suppressive macrophages
as crucial mediators of immunological tolerancewith the concomitant therapeutic implications in the
clinic.
INTRODUCTION
Myeloid cells with suppressive activity inhibit graft-reactive T cell
immunity and facilitate induction of regulatory T (Treg) cells,
together enabling the induction of transplantation tolerance
(Dugast et al., 2008; Garcia et al., 2010; Zhang et al., 2008).
An emerging consensus is that myeloid cells with immune regu-
latory function are contained within a population of CD11b+
mononuclear cells that express the myeloid differentiation
antigen Gr-1 (Bronte et al., 2000; Bronte et al., 1998). Given
the wide range of myeloid cells that might be included in this
category, identifying specific myeloid subsets capable of
mediating suppression, understanding the molecular basis of
their developmental requirements, and deciphering the mecha-
nisms that control their immune regulatory function represents
a difficult task.
In previously published work, we demonstrated that mono-
cytic cells that co-express CD11b, Gr-1, and the macrophage
colony-stimulating factor 1 receptor (CSF1R) accumulate in
cardiac allografts during tolerance induction, mediate T cell
suppression in vitro, and are required for long-term graft survival
induced by donor-specific transfusion plus anti-CD40L mAbImmunity 42, 1143–1158, June 16, 2015 ª2015 Elsevier Inc. 1143
(Garcia et al., 2010). Building upon these published observa-
tions, and the recognition that Gr-1 comprises the distinct and
independently regulated surface-expressed glycoproteins
Ly6C and Ly6G (Fleming et al., 1993), we demonstrate that
myeloid suppressive cells expressing CD11b+CSF1R+Ly6Clo
Ly6GCD169+ are responsible for transplantation tolerance.
Transcriptome analysis revealed that graft infiltrating immune
regulatory CD11b+CSF1R+Ly6CloLy6GCD169+ monocyte-
derived cells correspond to suppressive macrophages.
Blockade of the CD40L-CD40 costimulatory pathway pro-
motes the conversion of immunogenic CD11b+CSF1R+Ly6Chi
Ly6GCD169 into suppressive CD11b+CSF1R+Ly6CloLy6G
CD169+ macrophages through partial inhibition of interferon-g
(IFN-g) production in the transplanted allograft. The conversion
process requires CSF1, and interfering with this cytokine or its
receptor (CSF1R) abrogates the induction of indefinite allograft
survival. Mechanistically, we demonstrate that the dendritic
cell-specific ICAM-grabbing non-integrin (DC-SIGN, CD209a) is
upregulated in CD11b+CSF1R+Ly6CloLy6GCD169+-suppres-
sive macrophages and that simultaneous DC-SIGN engagement
by fucosylated ligands and TLR4 signaling is required for produc-
tion of immunoregulatory interleukin-10 (IL-10) associated with
immune regulation and prolonged allograft survival. In addition
to delineating a unique set of phenotypic markers and offering
newmechanistic insights into suppressivemacrophagedevelop-
ment and function during transplant tolerance, the data provide a
foundation for developing robust protocols potentially capable of
inducing immune regulatory macrophages for clinical use.
RESULTS
Suppressive Macrophages Accumulate during
Tolerance Induction
To characterizemyeloid cells that accumulate in allografts during
tolerance induction, we transplanted BALB/c hearts (H-2d) into
fully mismatched C57BL6/MaFIA (H-2b) recipient mice. These
recipient animals constitutively express green fluorescent pro-
tein (GFP) under the CSF1R promoter, permitting us to identify
recipient-derived graft-infiltrating myeloid cells that include
monocytes, dendritic cells (DCs), macrophages, and neutrophils
(Burnett et al., 2004). We treated groups of allograft recipients
with anti-CD40L mAb (clone MR1) or with control anti-immuno-
globulin G (IgG) mAb (Figure 1A), confirming previous work,
which demonstrated that anti-CD40L mAb induced indefinite
allograft survival, whereas rejection occurred by day 10 in the
IgG-treated controls (Jiang et al., 2011). We harvested donor
heart allografts on day 5 post-transplantation and analyzed
graft-infiltrating leukocytes by flow cytometry. When we gated
on live CD45+CD11b+CSF1RGFP+ recipient graft-infiltrating
myeloid cells, we discerned three major populations based on
differential expression patterns of Ly6C and Ly6G (Figure 1B).
Quantitative analysis revealed a higher frequency of CD11b+
CSF1R+Ly6CloLy6G cells and a lower frequency of CD11b+
CSF1R+Ly6ChiLy6G cells in the allografts of anti-CD40L
mAb-treated recipients compared to rejecting animals (p <
0.01). No differences in the frequencies of Ly6G cells were
observed between groups.
We tested the ability of each myeloid cell subset to inhibit anti-
CD3 and anti-CD28 stimulated CD8+ naive T cell proliferation1144 Immunity 42, 1143–1158, June 16, 2015 ª2015 Elsevier Inc.(Figure 1C). The CD11b+CSF1R+Ly6CloLy6G cell subset, but
not the CD11b+CSF1R+Ly6ChiLy6G cell subset obtained from
anti-CD40L mAb treated recipients, was potently suppressive.
The CD11b+CSF1R+Ly6CintLy6G+ cell subset obtained from
the anti-CD40L mAb-treated recipients also exhibited a modest
suppressive activity. None of the myeloid cell subsets obtained
from control IgG treated rejecting allografts exhibited in vitro
suppression. We next tested the ability of each myeloid cell
subset to induce expansion of CD4+Foxp3+ Treg cell in vitro
(Figure 1D). Consistent with suppression assay results, only
the CD11b+CSF1R+Ly6CloLy6G cells obtained from anti-
CD40L mAb-treated recipients, promoted the expansion of
CD4+Foxp3 expressing Treg cell numbers. Thus, the graft-infil-
trating CD11b+CSF1R+Ly6CloLy6G cell subset that accumu-
lates in anti-CD40L mAb-treated recipients possess many of
the properties reported to be associated with monocytic myeloid
suppressor cells, including their ability of inhibit CD8 T cell pro-
liferation (Gallina et al., 2006) and to promote CD4+Foxp3+
Treg cell number expansion (Huang et al., 2006).
Further gene array characterization of graft-infiltrating myeloid
CD11b+CSF1R+Ly6CloLy6G cells that accumulate in tolerized
recipients revealed that suppressive CD11b+CSF1R+Ly6Clo
Ly6G correspond to macrophages (Gautier et al., 2012), but
not dendritic cells (Miller et al., 2012) (Figure S1A). Morphological
examination of flow-sorted graft-infiltrating myeloid subsets
(Figure S1B) confirmed that myeloid CD11b+CSF1R+Ly6Clo
Ly6G cells are of monocytic origin.
Suppressive Macrophages Are Required for
Tolerance Induction
The transcriptional analyses of myeloid cell subsets revealed
significantly higher transcript expression of CX3CR1, F4/80,
CD206 (mannose macrophage receptor), CD68, CD172 (Sirp-a),
CD169, and MHC-II in Ly6Clo suppressive macrophages from
anti-CD40L mAb treated mice (Figure 2A). Flow cytometry
confirmed higher expression of these proteins on suppressive
macrophages, and we exploited their differential CD169 expres-
sion (Figure 2A and Figures S2A and S2B) along with the
availability of CD169 diphtheria toxin receptor (DTR) mice
(Miyake et al., 2007) to evaluate the suppressive function of
Ly6CloCD169+ macrophages in vivo. We transplanted BALB/c
hearts into anti-CD40L mAb-treated WT or CSF1RGFP+/
CD169DTR C57BL6 recipients and treated them with DT on
the day of transplantation to deplete recipient CD169+ cells.
Graft-infiltrating leukocytes by flow cytometry examined 5 days
later (Figure 2B) showed specific depletion of recipient suppres-
sive macrophages only in DT-treated animals. Depletion of
Ly6CloCD169+ macrophages in the anti-CD40L mAb-treated
recipients was associated with accumulation of memory or acti-
vated CD44hiCD62Llo CD8+ T cells on day 5 (Figures 2C and 2D)
and a reduced percentage of graft infiltrating CD4+Foxp3+ Treg
on day 21 posttransplant (Figure 2E). To verify that in vitro sup-
pressive Ly6CloCD169+ macrophages also exhibit inhibitory
function in vivo, we adoptively transferred CFSE-labeled CD8
T cells into anti-CD40L mAb-treated CD169DTR recipients and
evaluated their ability to proliferate measured by CFSE dilution
5 days after DT treatment (Figure 2F).Whereas CD8 T cells trans-
ferred into tolerized recipients did not proliferate in vivo, CD8
T cells underwent proliferation in the allografts of tolerized
Figure 1. Suppressive Macrophages Accumu-
late during Tolerance Induction
(A) Graft survival of control IgG mAb (rejecting) and anti-
CD40L mAb (tolerized) recipients of heterotopic cardiac
allografts (n = 20 mice/group). The shaded area depicts
heart allografts that were harvested at day 5 post-
transplantation for subsequent analyses.
(B) Representative and quantitative flow cytometry re-
sults for Ly6C and Ly6G expression in CD45+CD11b+
CSF1RGFP myeloid cell subsets from the allografts of
tolerized and rejecting recipients at day 5 post-trans-
plantation. Results represent mean ± SEM (n = 8 mice
per group).
(C) In vitro suppressive capacity of each myeloid subset
for CD8+ T cells. Proliferation was measured by CSFE
dilution after 96 hr by flow cytometry. Percentage of cell
proliferation is presented as mean ± SEM of five inde-
pendent experiments.
(D) In vitro Treg expansion of each myeloid subset.
Flow cytometric analysis indicates Foxp3 expression on
CD4 T cells after co-culture for 96 hr with myeloid
subsets. Percentage of Treg expansion is presented as
mean ± SEM of five independent experiments.
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Figure 2. Suppressive Macrophages Are Required for Tolerance Induction
(A) Heatmap derived frommicroarray data of selected myeloid markers that achieve p < 0.05 in myeloid subsets from the allografts of tolerized recipients at day 5
post-transplantation (means of n = 3 per group). Representative flow cytometry plots of the above myeloid markers on each myeloid subset. Data is repre-
sentative of three independent experiments.
(B) Representative and quantitative flow cytometry results of recipient myeloid cell subsets in the allografts of tolerized CSF1RGFP (wild-type) and CSF1RGFP
CD169DTR recipients at day 5 post-transplantation. Results represent mean ± SEM (n = 12 mice per group of 3 independent experiments).
(C and D) Representative and quantitative flow cytometry results depicting percentages (C) and surface memory/naive CD44/CD62L phenotypes (D) of graft
infiltrating CD8 T cells after CD169+ macrophage depletion. Results represent mean ± SEM (n = 12 mice per group of 3 independent experiments).
(legend continued on next page)
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recipients following depletion of CD169+ suppressive macro-
phages. Moreover, graft survival experiments showed that DT
induced in vivo depletion of CD169+-suppressive macrophages
resulted in graft rejection by day 30 despite tolerogenic treat-
ment with anti-CD40L mAb (p < 0.01) (Figure 2G). Thus,
Ly6CloCD169+-suppressive macrophages that accumulate in
the allografts of anti-CD40L mAb-treated recipients inhibit
T cell immune responses in vivo and are required for the induc-
tion of transplantation tolerance.
CD40L Blockade Inhibits Accumulation
of Immunogenic Macrophages
Graft-infiltrating myeloid subsets express CD40, but not CD40L
(Figures S3A and S3B), suggesting that tolerogenic properties
of the anti-CD40L mAb treatment are not due to a direct effect
on monocyte-derived cells because they do not express
CD40L. To test whether anti-CD40L mAb therapy induces
suppressive macrophages via inhibiting transmission of a
CD40-dependent signal on the myeloid cells, we attempted to
circumvent the effects of the anti-CD40L mAb blockade by
co-administering an agonistic anti-CD40 antibody FGK45.5, an
antibody that has been shown to transmit CD40-dependent sig-
nals to APC in the absence of CD40L (Bennett et al., 1998; Rolink
et al., 1996; Schoenberger et al., 1998). Administration of the
agonistic anti-CD40 mAb promoted the accumulation of
immunogenic Ly6Chi macrophages in the allograft (Figure 3A).
CD40-mediated accumulation of Ly6Chi macrophages might be
mediated by increased IFN-g expression in the allografts of toler-
ized recipients (Jutila et al., 1988). To test for a link between
CD40L-CD40 ligation and IFN-g-mediated Ly6Chi macrophage
activation in our transplant model, we measured IFN-g in the al-
lografts of untreated recipients, tolerized recipients, and tolerized
recipients co-treated with agonistic anti-CD40 mAb (Figure 3B).
These assays showed reduction of intra-graft IFN-g in the toler-
ized allografts compared to the untreated controls as previously
reported (Hancock et al., 1996) but restoration of intra-graft IFN-g
observed in the anti-CD40 mAb co-treated recipient. On the
contrary, agonistic CD40 ligation-mediated accumulation of
immunogenic Ly6Chi macrophages and increased intra-graft
IFN-g expression was not observed in tolerized CD40-deficient
(Cd40/) recipients (Figures 3C). Agonistic CD40 mAb abro-
gated the induction of tolerance despite CD40L blockade in
wild-type (WT), but not in Cd40/ recipients (Figure 3D). The
data suggest that anti-CD40L mAb-induced tolerance can be
abrogated by CD40 ligation, which favors the accumulation of
Ly6Chi immunogenic macrophages in the allograft through
IFN-g. To confirm this hypothesis, we treated tolerized recipients
with recombinant IFN-g and observed reduced intra-graft accu-
mulation of Ly6Clo macrophages on day 5 (Figure 3E) associated
with allograft rejection (Figure 3F). Conversely, partial IFN-g
blockade restored accumulation of Ly6Clo macrophages in the
allografts (Figure 3G) and reestablished indefinite allograft(E) Representative flow cytometry results depicting percentages of Foxp3 expre
recipients with or without CD169+ macrophage depletion. Results represent mea
(F) Effects of CD169+ macrophage depletion on in vivo T cell proliferation. CFS
CSF1RGFP CD169DTR recipients. Proliferation was measured in the allograft by
(n = 4 mice per group of 3 independent experiments).
(G) Effects of CD169+ macrophage depletion on graft survival in tolerized CSF1Rsurvival (Figure 3H) in tolerized recipients despite agonistic anti-
CD40 mAb treatment. Thus, costimulation blockade with anti-
CD40L mAb prevents IFN-g production and accumulation of
immunogenic Ly6Chimacrophages in the transplanted allografts.
CSF1 Mediates the Development of Suppressive
Macrophages
The expression of CSF1R in CD11b+CSF1R+Ly6CloLy6G
CD169+-suppressive macrophages suggests an involvement of
CSF1 in the development of these cells. We quantified CSF1
transcripts in transplanted mice by RT-PCR (Figure 4A) and
observed significant upregulation of CSF1 in the allografts of
anti-CD40L mAb-treated recipients. To test for a mechanistic
link between CSF1 and development of Ly6Clo-suppressive
macrophages in anti-CD40L mAb-treated recipient mice, we
transplanted BALB/c hearts into anti-CD40L mAb-treated toler-
ized C57BL6 recipients with or without neutralizing anti-CSF1
mAb (clone 5A1) at doses shown by others to inhibit their func-
tion in vivo (Gregory et al., 1992). Our results indicate that in vivo
CSF1 blockade abrogated intra-graft accumulation of Ly6Clo
suppressive macrophages (Figure 4B). CSF1 blockade also
prevented the in vivo expansion of CD4+ Foxp3+ Treg cell and
abrogated the induction of transplantation tolerance (Figures
4C and 4D). In vivo blockade of CSF1R receptor (clone
AFS98), at doses shown by others to inhibit their function in vivo
(Hashimoto et al., 2011), also abrogated tolerance, which sug-
gests that CSF1-CSF1R signaling is necessary for the develop-
ment of suppressive macrophages. Ly6Chi monocytes convert
into Ly6Clo macrophages (Arnold et al., 2007), the latter
being able to function as suppressive cells in tumor models
(Corzo et al., 2010). To test whether analogous mechanisms
apply in transplant tolerance, we isolated CD11b+CSF1R+
Ly6ChiLy6GGFP+ bone marrow monocytes from C57BL6/
MaFIA mice and transferred them into C57BL6/WT recipients
with or without anti-CD40L mAb and anti-CSF1 blocking mAb
(Figure 4E).Whereas the Ly6Chimonocytic precursors converted
into Ly6Clo macrophages in the allografts of anti-CD40L mAb-
treated mice, Ly6Chi monocytic precursors from anti-CSF1
mAb-treated recipient mice failed to convert and maintained a
Ly6Chi phenotype, similar to the untreated rejecting controls.
Additional in vitro experiments confirmed that CSF1 mediates
the conversion of Ly6Chi monocytic precursors into Ly6Clo
myeloid cells that were functionally able to inhibit CD8+ T cell
proliferation and promote Treg expansion (Figures 4F and 4G).
Our in vitro human data is consistent with this hypothesis and
suggests that CSF1, but not CSF2, promotes the development
of CD14 monocytes into suppressive monocyte-derived cells
that inhibit CD8 T cell proliferation and expand Foxp3-express-
ing Treg in vitro (Figure S4A) Thus, anti-CD40L mAb-induced
tolerance requires prevention of IFN-g production and upregula-
tion of CSF1, the latter driving conversion of monocytic precur-
sors into suppressive macrophages.ssing graft infiltrating CD4+ T cells on day 21 post-transplantation in tolerized
n ± SEM (n = 4 mice per group of 3 independent experiments).
E-labeled CD8+ T cells (5 3 106) were injected into tolerized CSF1RGFP and
CSFE dilution after 120 hr by flow cytometry. Results represent mean ± SEM
GFP and CSF1RGFP CD169DTR recipients (n = 12 mice/group).
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DC-SIGN Controls the Function of Suppressive
Macrophages
CSF1 upregulates the expression of the dendritic-cell-specific
intercellular adhesion molecule-3-grabbing non-integrin (DC-
SIGN, CD209a) (Choi et al., 2011; Domı´nguez-Soto et al.,
2011). Our gene array, real-time PCR, flow cytometry, and
immunofluorescence studies revealed higher expression of
DC-SIGN in macrophages obtained from the allografts of
anti-CD40L mAb-treated mice, non-rejecting human renal
transplant recipients, or in vitro derived CSF1-dependent
human macrophages (Figures 5A–5C, Figures S5A–S5D). To
test whether DC-SIGN is required for anti-CD40L mAb-induced
allograft survival, we transplanted BALB/c hearts into WT
C57BL6 recipients under the cover of anti-CD40L mAb,
together with either a blocking anti-DC-SIGN mAb or an iso-
type IgG control. DC-SIGN blockade abrogated the induction
of indefinite allograft survival in anti-CD40L mAb-treated mice
(Figure 5D). When we isolated and compared graft-infiltrating
leukocytes from anti-DC-SIGN mAb-treated recipients with
control mice (all treated with anti-CD40L mAb), we observed
similar frequencies of graft-infiltrating Ly6CloLy6G macro-
phages, suggesting that anti-DC-SIGN mAb treatment does
not prevent intra-graft accumulation of Ly6CloLy6G macro-
phages (Figure 5E). However, whereas flow-sorted graft-
infiltrating CD11b+CSF1R+Ly6CloLy6G macrophages from
tolerized recipients suppressed CD8+ T cell proliferation and
expanded CD4+Foxp3+ Treg in vitro, flow-sorted CD11b+
CSF1R+Ly6CloLy6G macrophages obtained from tolerized
recipients treated with anti-DC-SIGN mAb did not exhibit either
of these immune regulatory functions (Figure 5F). Finally, we
flow-sorted CD11b+CSF1R+Ly6CloLy6G-suppressive macro-
phages from anti-CD40L mAb-treated recipients and assessed
their ability to suppress CD8+ T cell proliferation and expanded
CD4+Foxp3+ Treg following in vitro blockade of DC-SIGN by
adding anti-DC-SIGN mAb to the cell cultures (Figure 5G).
Thus, DC-SIGN expression is required for the immune regula-
tory function of suppressive macrophages that mediate indef-
inite allograft survival. Using DC-SIGN deficient (CD209a/)
and CD169DTR tumor bearing mice our data revealed that
depletion of CD169+ macrophages or absence of DC-SIGN
significantly reduces in vivo tumor growth (Figure S6A).
Together with data from renal cell carcinoma patients showing
increased DC-SIGN expression at the tumor site (Figure S6B),Figure 3. CD40L Blockade Inhibits Accumulation of Immunogenic Mac
(A) Representative and quantitative flow cytometry results of recipient myeloid cel
with agonistic CD40 mAb. Results represent mean ± SEM (n = 4 mice per group
(B) IFN-g expression in cardiac allografts. Cardiac allografts were harvested 5 day
at 100 mg/mouse on days 0 and +1 relative to transplantation. Recombinant mo
Supernatants of single cell suspensions were analyzed for IFN-g measured by
(**p < 0.01).
(C) Representative and quantitative flow cytometry results of recipient myeloid ce
agonistic CD40 mAb treatment. Results represent mean ± SEM (n = 4 mice per
(D) Effects of CD40 ligation on graft survival in tolerized WT and CD40 deficient
(E) Representative and quantitative flow cytometry results of recipient myeloid cel
IFN-g treatment (4 3 105 units/day for 5 days). Results represent mean ± SEM (n
(F) Effects of recombinant IFN-g on graft survival in tolerized WT recipients (n =
(G) Representative and quantitative flow cytometry results of recipient myeloid c
CD40 mAb with or without anti-IFN-g mAb treatment. Results represent mean ±
(H) Effects of partial IFN-g blockade on graft survival in tolerized wild-type recipithis suggests that DC-SIGN+ macrophages also participate
in the immune regulatory function that controls tumor
progression.
Fucosylated DC-SIGN Ligands Are Required for
Macrophage-Mediated Suppression and Tolerance
DC-SIGN binds to carbohydrates containing mannose or fucose
residues, such as LewisX (van Liempt et al., 2006).We next inves-
tigated the role of fucosylated LewisX in the induction of trans-
plantation tolerance using the a1,3/4-fucosyltransferases
(FucTs) IV-VII double-deficient (dKO) donor mice, which display
impaired LewisX expression (Lowe, 2002). We next used FucT-IV
and FucT-VII mice as donors to evaluate the effects of LewisX
inhibition on suppressive Ly6Clo macrophages and tolerance.
Figure 6A indicates that the LewisX expression was significantly
reduced in tolerized dKO donor allografts, which was associated
with acute rejection despite tolerogenic treatment with anti-
CD40L mAb (Figure 6B). We next compared recipient graft-infil-
trating leukocytes from donor dKO and WT allografts treated
with anti-CD40L mAb, and we observed similar frequencies of
graft-infiltrating Ly6CloLy6G macrophages (Figure 6C). These
results suggest that LewisX deficiency does not prevent intra-
graft accumulation of Ly6Clo macrophages. However, whereas
flow-sorted graft-infiltrating Ly6Clo macrophages from WT
donors suppressed CD8+ T cell proliferation and expanded
CD4+Foxp3+ Treg cell in vitro, the flow-sorted Ly6Clo macro-
phages obtained from dKO donor allografts did not exhibit
neither of these immune regulatory functions (Figure 6D). We
next investigated whether lacto-N-fucopentaose III (LNFPIII), a
LewisX containing pentasaccharide that binds to DC-SIGN
(Meyer et al., 2005), could overcome the fucosylated LewisX defi-
ciency in dKO donor allograft recipients (Figure 6E). Our results
indicate that unlike dextran (which does not bind to CD209a-
mDC-SIGN [Takahara et al., 2004]), LNFPIII is able to restore
tolerance in transplant recipients containing dKO donor allo-
grafts. Flow-sorted graft-infiltrating Ly6Clo macrophages from
LNFPIII-treated dKO donor allograft tolerized recipients were
able to suppress CD8+ T cell proliferation and expanded CD4+
Foxp3+ (Figure 6F). Our results indicate that in vivo LNFPIII treat-
ment restores the suppressive activity of Ly6Clo macrophages.
Thus, LewisX-mediated DC-SIGN ligation is necessary for the
immune regulatory function of suppressive macrophages and
for the induction of indefinite allograft survival.rophages
l subsets in the allografts of tolerizedWT recipients with or without co-treatment
of 3 independent experiments).
s after transplantation from each group. Agonistic anti-CD40mAbwas injected
use IFN-g was injected at 4 3 105 units/day for 10 days (n = 4 mice/group).
ELISA. Bar graphs represent mean ± SEM of three independent experiments
ll subsets in the allografts of tolerized CD40 deficient recipients with or without
group of 3 independent experiments).
recipients (n = 8 mice/group).
l subsets in the allografts of tolerizedWT recipients with or without recombinant
= 4 mice per group of 3 independent experiments).
8 mice/group).
ell subsets in the allografts of tolerized WT recipients co-treated with agonistic
SEM (n = 4 mice per group of 3 independent experiments).
ents co treated with agonistic CD40 mAb (n = 8 mice/group).
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IL-10 Is Essential for DC-SIGN-Mediated Suppression
Fucose-specific DC-SIGN signaling results in production of
IL-10 (Caparro´s et al., 2006; Gringhuis et al., 2014). We observed
a significant IL-10 upregulation in the allografts of anti-CD40L
mAb-treated WT recipients compared to untreated rejecting
controls (Figure 7A). In contrast, IL-10 was essentially absent
in anti-CD40L mAb-treated DC-SIGN-deficient (CD209a/)
recipient mice. Among graft-infiltrating leukocytes, we detected
the highest IL-10 expression in Ly6Clo macrophages obtained
from anti-CD40L mAb treated recipients, but the same Ly6Clo
macrophages obtained from the allografts of CD209a/ recipi-
ents exhibited significant less IL-10 expression despite anti-
CD40L mAb treatment (Figure 7A; Figure S7A). To specifically
test whether IL-10 is required for regulatory macrophage
function, we sorted intra-graft Ly6Clo macrophages from anti-
CD40L mAb treated IL-10-deficient (Il10/) recipient mice and
tested their ability to suppress CD8+ T cell proliferation and to
expand CD4+Foxp3+ Treg cell in vitro (Figure 7B). In the absence
of IL-10, Ly6Clo macrophages did not exhibit either of these
immune regulatory functions despite tolerogenic treatment
with anti-CD40L mAb. Using CD209a/recipient mice, we
next investigated whether recombinant IL-10 could restore the
suppressive function of Ly6Clo graft-infiltrating macrophages
(Figure 7C). Although intra-graftCD209a/Ly6Clomacrophages
were unable to suppress CD8+ T cell proliferation and to expand
CD4+Foxp3+ Treg in vitro, IL-10 addition rescued the immune
regulatory function of CD209a/ Ly6Clo macrophages. Thus,
graft-infiltrating DC-SIGN+Ly6Clo macrophages exert their im-
mune regulatory function in part through an IL-10-dependent
mechanism. Because crosstalk between DC-SIGN and TLR4
signaling is required for fucose binding-meditated production
of IL-10 (Gringhuis et al., 2007; Gringhuis et al., 2014), we
explored the effects of TLR4 deficiency in suppressive macro-
phages using tolerized TRL4 recipients, and showed that in the
absence of TLR4 stimulation, IL-10 production was reduced in
Ly6Clo macrophages (Figure 7D), and their in vitro suppressive
function was defective (Figure 7E). To demonstrate that syner-
gistic DC-SIGN and TRL4 signaling was necessary for IL-10 pro-
duction, we cultured bone marrow cells from WT, CD209a/,
and TRL4-deficient (Tlr4/) mice and stimulated them with the
DC-SIGN ligand LewisX and the TLR4 ligand high mobility group
box 1(HMGB1) (Figure 7F). Simultaneous DC-SIGN and TRL4
signaling was necessary for optimal IL-10 production, and inter-
fering with one of the signals resulted in impaired IL-10 produc-
tion. We investigated whether ligation of DC-SIGN and/or TLR4
resulted in an increased inhibitory function (Figure 7G). AdditionFigure 4. CSF1 Mediates the Development of Suppressive Macrophag
(A) CSF1 expression in cardiac allografts. Cardiac allografts were harvested 5 da
suspensions were analyzed for CSF1 measured by real-time PCR. Bar graphs re
(B) Representative and quantitative flow cytometry results of recipient myeloid ce
mAb. Results represent mean ± SEM (n = 4 mice per group of 3 independent ex
(C) Representative and quantitative flow cytometry results of Foxp3 expression
plantation following anti-CSF1 mAb treatment. Results represent mean ± SEM (n
(D) Effects of CSF1 and CSF1R blockade on graft survival in tolerized WT recipie
(E) Representative and quantitative flow cytometry results of adoptively transferre
mAb ± anti-CSF1 mAb 5 days after transplantation. Results represent mean ± S
(F) Representative and quantitative flow cytometry results of in vitro cultured Ly6
represent mean ± SEM of three independent experiments.
(G) Suppressive function of Ly6Chi bone marrow cells after CSF1 or IFN-g in vitroof both DC-SIGN and TLR4 agonists resulted in the highest
suppressive function observed inmonocyte-derived human cells
in comparison with each of the ligands alone. Thus, DC-SIGN+
macrophages stimulated though DC-SIGN and TLR4 are nega-
tive regulators of the immune response and that their manipula-
tion will open new avenues for therapeutic intervention either by
inhibiting their function (i.e., in cancer patients) or by enhancing
their suppressive effects and promoting their expansion (i.e., in
transplant recipients).
DISCUSSION
We demonstrate here that DC-SIGN-expressing macrophages
are required for the induction of transplantation tolerance.
DC-SIGN is a type II transmembrane C-type lectin with a carbo-
hydrate recognition domain, which is expressed in human DCs
and macrophages (Geijtenbeek et al., 2000; Soilleux et al.,
2002), and is involved in multiple aspects of the immunological
response (van Kooyk and Geijtenbeek, 2003). Broxmeyer and
colleagues reported that in vitro differentiation of monocytes in
the presence of M-CSF and IL-4, which induces DC-SIGN
expression (Martinez et al., 2006), are less efficient inductors of
allogeneic mixed lymphocyte reactions (Li et al., 2004; Li et al.,
2005). Here, we extend these findings to newly demonstrate
that DC-SIGN+ macrophages inhibit T cell proliferation in vitro
and in vivo in an experimental mouse model of solid organ trans-
plantation. Additionally, we demonstrate that human DC-SIGN
expressing macrophages stimulated with M-CSF and IL-4
(Figure S5D) induced the expansion of Foxp3-expressing Treg
from allogeneic naive CD4+ T cell precursors in vitro, whereas
macrophages treated with GM-CSF and IL-4 did not drive Treg
expansion (Figure S4A).
The ability of murine DC-SIGN+ macrophages to promote
IL-10-mediated transplantation tolerance requires two synergis-
tic signals: DC-SIGN engagement by fucosylated ligands and
TLR4 signaling. The CDR domain of human DC-SIGN recognizes
fucosylated Lewis glycans (van Liempt et al., 2006) expressed by
self and non-self antigens (Geijtenbeek et al., 2004). In humans,
DC-SIGN ligation potentiates the secretion of IL-10 (Geijtenbeek
et al., 2003). Because DC-SIGN macrophages secrete IL-10
upon fucose ligand engagement (Gringhuis et al., 2014) and
participate in the generation of regulatory T cells (Cai et al.,
2013; Smits et al., 2005), DC-SIGN could actively contribute to
the maintenance of an immunosuppressive tissue environment,
as proposed by Yvette van Kooyk’s laboratory (van Gisbergen
et al., 2005). Indeed, DC-SIGN ligation by non-immune cells,es
ys after transplantation from tolerized and rejecting recipients. Total single cell
present mean ± SEM of three independent experiments (**p < 0.01).
ll subsets in the allografts of tolerized WT recipients co-treated with anti-CSF1
periments).
on CD4 T cells in the allografts of tolerized recipients on day 21 post-trans-
= 4 mice per group of 3 independent experiments).
nts (n = 12 mice/group).
d CSF1R+Ly6Chi bonemarrow cells into recipient mice treated with anti-CD40L
EM (n = 3 mice per group of 3 independent experiments).
Chi bone marrow cells with either recombinant CSF1 or IFNg for 96 hr. Results
treatment. Results represent mean ± SEM of three independent experiments.
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Figure 5. DC-SIGN Controls the Function of Suppressive Macrophages
(A and B) Heatmap derived frommicroarray data (A) and flow cytometry expression (B) of DC-SIGN inmyeloid subsets from the allografts of tolerized and rejecting
recipients at day 5 post-transplantation (means of n = 3 per group). Flow cytometry plots are representative of three independent experiments.
(C) Quantitative immunofluorescent analysis of tolerized and rejecting allografts at day 5 post-transplantation. Bar graphs represent frequency of DCSIGN+ cells
expressed as percentage of a total of 1,000 DAPI nucleated cells from the allografts of tolerized and rejecting mice. Results represent mean ± SEM of 10 tissue
sections from 4 cardiac allografts per group (**p < 0.01).
(D) Effects of DC-SIGN blockade and DC-SIGN deficiency on graft survival in tolerized WT recipients (n = 12 mice/group).
(E) Representative and quantitative flow cytometry results of recipient myeloid cell subsets in the allografts of tolerized WT recipients co-treated with anti-DC-
SIGN mAb. Results represent mean ± SEM (n = 4 mice per group of 3 independent experiments).
(F) Representative and quantitative flow cytometry results of in vitro suppressive capacity and Treg expansion of Ly6Clo macrophages from tolerized recipients
co-treated with anti-DC-SIGN. Results represent mean ± SEM (n = 4 mice per group of 3 independent experiments).
(G) Suppressive function of Ly6Clo macrophages from tolerized recipients after in vitro treatment with anti-DC-SIGN mAb. Results represent mean ± SEM of
three independent experiments.
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such as pathogens and tumor tissue results in immune escape
(Geijtenbeek and Gringhuis, 2009), suggesting that both tumor
and pathogens have ways to escape immune activation by
targeting DC-SIGN. Consistent with this hypothesis our data
reveals that depletion of CD169+ macrophages or absence of
DC-SIGN significantly reduces in vivo tumor growth (Figure S6A),
suggesting that DC-SIGN+macrophagesmight participate in the
immune regulatory function that controls tumor progression (Fig-
ure S6B). Our transplant results indicate that fucosylated glycans
are present in the donor allografts of tolerized recipients that
serve as ligands of DC-SIGN expressing macrophages. Using
fucosyltransferase-deficient donor heart allografts inhibits the
expression of LewisX glycoproteins and prevents the induction
of indefinite allograft survival despite tolerogenic treatment
with anti-CD40L mAb treatment. This suggests common mech-
anisms of immune regulation following engagement of DC-SIGN
by tumor and transplant microenvironment via LewisX recogni-
tion that lead to the production of IL-10 producing macrophages
(Domı´nguez-Soto et al., 2011; Nonaka et al., 2008; van Gisber-
gen et al., 2005).
Induction of transplantation mediated by DC-SIGN+-sup-
pressive macrophages depends on simultaneous TLR4
signaling. DC-SIGN signaling crosstalk with TLR4 has been
demonstrated to mediate IL-10 production (Geijtenbeek et al.,
2003; Gringhuis et al., 2007; Gringhuis et al., 2014). Here we
report that DC-SIGN+ macrophages from TLR4-deficient heart
recipients produce significantly less IL-10 and do not exhibit
suppressive function. Consistent with these results, a recent
study indicates that during peripheral tolerance, DC-SIGN
and TLR4 are required for IL-10 secretion and decreased
T cell proliferation in mixed leukocyte reactions possibly
caused by an increased frequency of Treg cell, which is asso-
ciated with a high fucosyltransferase expression (Garcı´a-Vallejo
et al., 2014). In transplantation, while absence of absence of
innate MyD88 signaling prevents acute allograft rejection and
promotes inducible allograft acceptance (Goldstein et al.,
2003; Walker et al., 2006), it is possible that specific signaling
molecules of the MyD88 pathway, such as TRL4, might have
a critical role in the induction of tolerance mediated by sup-
pressive myeloid cells. In this respect, the TLR4 agonist
HMGB1, which is upregulated during tissue damage associ-
ated with ischemia reperfusion (Wu et al., 2007) and surgical
transplantation (Huang et al., 2007), has been recently demon-
strated to enhance the immune-suppressive capacity of
myeloid-derived suppressor cells through the production of
IL-10 (Parker et al., 2014).Figure 6. Fucosylated DC-SIGN Ligands Are Required for Macrophage
(A) Quantitative immunofluorescent analysis of tolerized and rejecting allografts a
expressed as percentage of a total of 1,000 DAPI nucleated cells from tolerized m
allografts. Results represent mean ± SEM of ten tissue sections from four cardia
(B) Effects of LewisX deficiency on graft survival in tolerized WT recipients (n = 1
(C) Representative and quantitative flow cytometry results of recipient myeloid
allografts. Results represent mean ± SEM (n = 4 mice per group of 3 independen
(D) Representative and quantitative flow cytometry results of in vitro suppressiv
tolerized mice receiving WT and FucT IV-VII dKO donor allografts. Results repre
(E) Effects of Lacto-N-fucopentaose III (LNFPIII) on graft survival in tolerized wild
(F) Representative and quantitative flow cytometry results of in vitro suppressi
of tolerized mice receiving WT and FucT IV-VII dKO donor allografts following ad
of 3 independent experiments).
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SIGN+-suppressive macrophages mediate the induction of
transplantation tolerance, revealing a previously unknown
function of mouse DC-SIGN. Our delineation of a specific
cell-surface phenotype for immunoregulatory, graft-protective
suppressive macrophages in transplantation, as well as the
mechanistic insights underlying the requirements for their differ-
entiation in vivo, have important implications for understanding
and potentially manipulating pathogenic immune responses.
The C-type lectin DC-SIGN (CD209a) has a critical function in
the induction of transplantation tolerance as demonstrated by
its absence or in vivo blockade andmight be used as phenotypic
marker to define immune regulatory macrophages. The data
provide a framework for developing CSF1-based in vitro
protocols to induce therapeutic macrophages for clinical use
to prevent transplant rejection and suggest that depleting or
blocking suppressive macrophage development by targeting
CSF1, which upregulates the expression of DC-SIGN, could be
exploited to enhance anti-tumor immunity.
EXPERIMENTAL PROCEDURES
Mice
BALB/c, C57BL/6, C57BL/6-Foxp3tm1Flv/J, B6.129P2-Cd40tm1Kik/J, and
B6.B10ScN-Tlr4lps-del/JthJ mice 8 weeks of age were purchased from The
Jackson Laboratory. DC-SIGN-deficient mice (DC-Sign-KO, B6 [FVB]-
Cd209atm1.1Cfg/Mmcd) were from the Mutant Mouse Regional Resource
Centers, Consortium for Functional Glycomics (Scripps Res. Institute). The
alpha(1,3)fucosyltransferases FucT-IV and FucT-VII double-deficient mice
were from John Lowe (University of Michigan). The C57BL/6-Tg (Csf1r-
EGFP-NGFR/FKBP1A/TNFRSF6) 2Bck/J MaFIA mice from D. Cohen (Univer-
sity of Kentucky) (Burnett et al., 2004). The C57BL/6 CD169DTRmice have been
previously described (Miyake et al., 2007). All experiments were performed
with age- and sex-matched mice in accordance with Institutional Animal
Care and Utilization Committee-approved protocols.
Vascularized Heart Transplantation
BALB/c hearts were transplanted as fully vascularized heterotopic grafts
into C57BL/6 mice as previously described (Corry et al., 1973). Recipient
mice were treated with 250 mg anti-CD40L mAb (clone MR1, BioXcell) for
tolerance induction on days 0, 2, and 4 as previously described (Jiang et al.,
2011). Graft function was monitored every other day by abdominal palpation.
Untreated control mice received hamster IgG in PBS. Rejection was defined
as complete cessation of a palpable beat and confirmed by direct visualization
at laparotomy.
In Vivo Cell Depletion
For depletion of CD169 expressing CD11b+CSF1R+Ly6CloLy6G- regulatory
macrophages heterozygous CD169-DTR recipients were injected intraperito-
neally (i.p.) with 10 ng/g body weight of DT (Sigma-Aldrich) 24, 48, andMediated Suppression
t day 5 post-transplantation. Bar graphs represent frequency of Lewis X+ cells
ice receiving WT and fucosyltranferase (Fut) IV and VII double-deficient donor
c allografts per group (**p < 0.01).
2 mice/group).
cell subsets in tolerized mice type receiving WT and FucT IV-VII dKO donor
t experiments).
e capacity and Treg expansion of Ly6Clo macrophages from the allografts of
sent mean ± SEM (n = 4 mice per group of 3 independent experiments).
-type recipients (n = 8 mice/group).
ve capacity and Treg expansion of Ly6Clo macrophages from the allografts
ministration of LNFPIII. Results represent mean ± SEM (n = 4 mice per group
(legend on next page)
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72 hr after transplantation (Miyake et al., 2007). Ly6G+ cell depletion was
induced with anti-Ly6G mAb clone 1A8 (BioXcell) injected at 0.5 mg i.p. on
days –3, –2, and –1 relative to transplantation as previously described (Daley
et al., 2008; Garcia et al., 2010).
Antibody-Mediated In Vivo Treatment
Agonistic anti-CD40 mAb (clone FGK4.5 mAb) was produced by BioXcell.
CD40-mediated priming independent of CD40L was achieved by intravenous
(i.v.) injection of 100 mg of agonistic anti-CD40mAb on days 0 and +1 relative to
transplantation (Gorbachev and Fairchild, 2004). Blocking antibody to IFN-g
(Clone R4-6A2) was produced by BioXcell. Anti-IFN-g mAb was injected at
500 mg on days 0 and +1 relative to transplantation. Blocking antibody to
CSF1 (clone 5A1) (Lokeshwar and Lin, 1988) and CSF1R (clone AFS98)
(Sudo et al., 1995) were produced by BioXcell. Anti-CSF1 mAb was injected
at 150 mg i.p. on days 1, +1, +2, +3, and +4 relative to transplantation,
which is known to neutralize the biological functions of CSF1 in vivo (Gregory
et al., 1992). Anti-CSF1R mAb was injected at 2 mg/mouse on day 5 and
0.5 mg/mouse on days 4 and 3, which is known to neutralize the biological
functions of CSF1R in vivo (Hashimoto et al., 2011). Blocking antibody to
DC-SIGN (CD209a) (Cheong et al., 2010) was mAb was purified from culture
supernatant, grown in a CELLine Flask (BD) in serum-free medium (PFHM-II;
Invitrogen) and injected at 250 mg i.p. on days +1, +2, +3, and +4 relative to
transplantation.
Mouse Suppression Assay
Spleens of C57BL/6 or C57BL/6-Foxp3tm1Flv/J (H-2b) mice were gently
dissociated into single-cell suspensions, and red blood cells were removed
using hypotonic ACK lysis buffer. Splenocytes were either stained with anti-
CD4 mAb, or labeled with CFSE at 5 mM concentration (Molecular probes - In-
vitrogen) followed by staining with anti-CD8 mAb for 30 min on ice. Responder
FoxP3+CD4+ and CFSE+CD8+ T cells were sorted using FACS Aria II (BD Bio-
sciences) with a purity > 98%. Spleens of BALB/c (H-2d) mice were gently
dissociated into single-cell suspensions and were enriched for CD11c+ cells
using the EasySep Mouse CD11c Positive Selection Kit (StemCell). Enriched
CD11c+ splenocytes were stained with anti-mouse CD11cmAb and sorted us-
ing FACS Aria II (BD Biosciences) and were used together with anti-CD3 plus
CD28 mAb (1 mg/ml) as stimulators. Stimulated FoxP3+CD4+ or CFSE+CD8+
T cells were cultures with graft infiltrating CD11b+CSF1R+Ly6ChiLy6G-,
CD11b+CSF1R+Ly6CloLy6G-, and CD11b+CSF1R+Ly6CintLy6G+myeloid cells
for 4 days at 37C in a 5%CO2 incubator. T cell proliferation was measured by
flow cytometric analysis of CFSE dilution on CD8+ T cells. Treg expansion was
measured by flow cytometric analysis of Foxp3-RFP on CD4+ T cells.
ACCESSION NUMBER
The GEO accession number for the microarray data reported in this paper is
GSE68648.Figure 7. IL-10 Is Essential for DC-SIGN Mediated Suppression
(A) IL-10 expression in cardiac allografts and Ly6Clo macrophages. Cardiac allog
were harvested 5 days after transplantation. Total single cell suspensions and L
represent mean ± SEM of three independent experiments (**p < 0.01).
(B) Representative and quantitative flow cytometry results of in vitro suppressiv
tolerized IL-10 deficient recipient mice. Results represent mean ± SEM (n = 4 mi
(C) Representative and quantitative flow cytometry results of in vitro suppress
of tolerized DC-SIGN deficient recipient mice receiving in vitro IL-10 stimulation
3 independent experiments).
(D) IL-10 expression in cardiac allografts. Cardiac allografts from tolerized WT an
cell suspensions were analyzed for IL-10 measured by real-time PCR. Bar graph
(E) Representative and quantitative flow cytometry results of in vitro suppressiv
tolerized TLR4 deficient recipient mice. Results represent mean ± SEM (n = 4 m
(F) IL-10 expression in stimulated bone marrow cells from WT, DC-SIGN-deficie
(10 mg/ml) and recombinant HMGB1 (10 mg/ml) for 72 hr in vitro stimulation (contro
for IL-10 measured by ELISA. Results represent mean ± SEM of three independe
(G) Representative and quantitative flow cytometry results for in vitro suppressive
mean ± SEM of three independent experiments (*p < 0.05, **p < 0.01).
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